iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD.